Prostate cancer Cancer Malignant neoplasm of prostate
Conditions
Interventions
Current interventions as of 14/08/2013:
1. Radical prostatectomy
2. Radical radiotherapy
3. Active monitoring: monitoring of the disease including prostate specific antigen levels
Previous interventi
Sponsors
University of Oxford (UK)
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: Men aged 50-69 years from the community, localised prostate cancer for eligibility for randomisation
Exclusion criteria
Exclusion criteria: Not provided at time of registration.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Current primary outcome measures as of 18/03/2019: 1. Disease-specific survival at 15 years. 2. Disease progression (biochemical and clinical). 3. Treatment complications (long term). 4. Lower urinary tract symptoms. 5. Psychosocial impact of treatment including generic health status, quality of life and sexual function. 6. Prostate cancer specific survival. 7. Overall survival. Previous primary outcome measures as of 14/08/2013: 1. Disease-specific survival at 10 years Previous primary outcome measures as of 27/09/2010: 1. Disease progression (biochemical and clinical) 2. Treatment complications 3. Lower urinary tract symptoms 4. Psychosocial impact of case-finding and treatment including generic health status, quality of life and sexual function 5. Prostate cancer specific survival 6. Overall survival Previous primary outcome measures as of 14/10/2002: 1. Disease progression (biochemical and clinical) 2. Treatment complications 3. Lower urinary tract symptoms 4. Psychosocial impact of case-finding and treatment including generic health status, quality of life and sexual function | — |
Secondary
| Measure | Time frame |
|---|---|
| Current secondary outcome measures as of 21/07/2021: 1. Overall survival 2. Disease progression (biochemical and clinical) 3. Lower urinary tract symptoms 4. Psychosocial impact of cancer diagnosis and treatment including generic health status, quality of life and sexual function 5. Cost-effectiveness of the treatments 15 year median analysis no health economic analysis Previous secondary outcome measures added 14/08/2013: 1. Overall survival 2. Disease progression (biochemical and clinical) 3. Lower urinary tract symptoms 4. Psychosocial impact of cancer diagnosis and treatment including generic health status, quality of life and sexual function 5. Cost-effectiveness of the treatments | — |
Countries
England, United Kingdom
Outcome results
None listed